Skip to main content

Table 4 Multiple reaction monitoring (MRM) transitions for quantification of the nine target compounds

From: Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese medicine-defined constitutional types of healthy Chinese subjects: study protocol for a randomized controlled trial

Compound abbreviations* Monitoring Mode Parent (m/z) Product (m/z) Tube lens (V) Collision energy (eV) Retention times (min)
CCS [M + H]+ 285.16 270.30 99 23 6.43
CCSG [M + H]+ 447.24 285.30 98 20 4.89
FAN [M + H]+ 623.44 381.40 130 40 4.89
PAL [M + H]+ 352.23 336.30 89 29 5.44
5-O-M [M + H]+ 453.27 291.30 108 22 6.01
ONO [M + H]+ 431.25 269.30 97 17 6.00
FOR [M + H]+ 269.20 197.30 97 34 7.32
AST-IV [M + Na]+ 807.53 627.40 221 49 8.69
BER [M + H]+ 336.19 320.28 94 30 5.38
  1. *The compound abbreviations and their associated terms:
  2. AST-IV: astragaloside IV; BER: berberine; CCS: calycosin; CCSG: calycosin-7-O-β-D- glucoside; FAN: fangchinoline; FOR: formononetin; ONO: ononin; PAL: palmatine; 5-O-M: 5-O-methylvisammioside.